Sequence-Verified cDNA Clones

Catalog nos. 97002.V, 97001.V, 97002.MmV

Version C
February 3, 2003
25-0627
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of Contents</td>
<td>iii</td>
</tr>
<tr>
<td>Contents and Storage</td>
<td>v</td>
</tr>
<tr>
<td>Overview</td>
<td>1</td>
</tr>
<tr>
<td>Using Sequence-Verified Clones</td>
<td>4</td>
</tr>
<tr>
<td>Technical Service</td>
<td>7</td>
</tr>
<tr>
<td>Purchaser Notification</td>
<td>9</td>
</tr>
</tbody>
</table>
Contents and Storage

Shipping and Storage

The Sequence-Verified Human and Mouse cDNA Clones are supplied as glycerol stocks. The individual cDNA clones are shipped at room temperature and cDNA Library is shipped at -20°C. Upon receipt, store the clones and library at -80°C.

Types of Products

This manual is included with the following products:

<table>
<thead>
<tr>
<th>Product</th>
<th>Catalog no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sequence-Verified Human cDNA Clones</td>
<td>97002.V</td>
</tr>
<tr>
<td>Sequence-Verified Human cDNA Library</td>
<td>97001.V</td>
</tr>
<tr>
<td>Sequence-Verified Mouse cDNA Clones</td>
<td>97002.MmV</td>
</tr>
</tbody>
</table>

Contents

Clones

Each tube of the Sequence-Verified cDNA Clone Collection contains the gene of interest in an appropriate vector (see page 3 for vector information) transformed into GeneHogs® E. coli. Each clone is supplied in 500 µl of LB media containing 8% glycerol and 100 µg/ml carbenicillin.

Library

Each well of the 96-well plate contains a distinct Sequence-Verified Human cDNA Clone in an appropriate vector (see page 3 for vector information) transformed into GeneHogs® E. coli. Each clone is supplied in 100 µl of LB media containing 8% glycerol and 100 µg/ml carbenicillin.

Genotype of GeneHogs® E. coli

The genotype of GeneHogs® E. coli (also known as HS996) is:

F* mcrA Δ(mrr-hsdS-RM-S-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 deoR araD139 Δ(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG fhuA::IS2 (confers phage T1 resistance)

Quality Control

The Sequence-Verified cDNA Clones are qualified by growing each clone in LB medium containing 100 µg/ml carbenicillin at 37°C overnight. The clone must exhibit growth under these conditions.

To verify the absence of phage contamination, 0.5-1 ml of E. coli are added to LB top agar and poured onto LB plates. A small aliquot of the clone culture is streaked on top agar. After overnight incubation, no plaques must be detected.
## Accessory Products

Additional products that may be used with the Sequence-Verified Clones are available from Invitrogen. Ordering information is provided below.

<table>
<thead>
<tr>
<th>Item</th>
<th>Quantity</th>
<th>Catalog no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP Clonase™ Enzyme Mix</td>
<td>20 reactions</td>
<td>11789-013</td>
</tr>
<tr>
<td>One Shot® TOP10 Chemically Competent E. coli</td>
<td>10 reactions</td>
<td>C4040-10</td>
</tr>
<tr>
<td>One Shot® TOP10 Electrocompetent E. coli</td>
<td>20 reactions</td>
<td>C4040-03</td>
</tr>
<tr>
<td>One Shot® MAX Efficiency® DH10B™ T1 Phage-Resistant Cells</td>
<td>10 reactions</td>
<td>C4040-50</td>
</tr>
<tr>
<td>imMedia™ Amp Agar</td>
<td>20 pouches</td>
<td>Q601-20</td>
</tr>
<tr>
<td>Ampicillin</td>
<td>20 ml (10 mg/ml)</td>
<td>11593-019</td>
</tr>
<tr>
<td>Carbenicillin</td>
<td>5 g</td>
<td>10177-012</td>
</tr>
<tr>
<td>pDONR™207</td>
<td>6 µg</td>
<td>12213-013</td>
</tr>
<tr>
<td>pDONR™221</td>
<td>6 µg</td>
<td>12536-017</td>
</tr>
<tr>
<td>cDNA Primer Pair</td>
<td>25 µl (1 mM)</td>
<td>GF200.primer</td>
</tr>
<tr>
<td>S.N.A.P.™ MiniPrep Kit</td>
<td>100 reactions</td>
<td>K1900-01</td>
</tr>
<tr>
<td>S.N.A.P.™ MidiPrep Kit</td>
<td>20 reactions</td>
<td>K1910-01</td>
</tr>
<tr>
<td>T7 Primer</td>
<td>N560-02</td>
<td>327 pmoles</td>
</tr>
<tr>
<td>Sp6 Primer</td>
<td>N550-02</td>
<td>342 pmoles</td>
</tr>
</tbody>
</table>
Overview

Introduction
The Sequence-Verified cDNA Clone Collection encompasses over 45,000 unique human clones and ~15,000 unique mouse clones. Clones in this collection are characterized to confirm identity and minimize redundancy. Based on the 3′ end sequence, one high-quality cDNA clone representing a unique gene is chosen from each NCBI UniGene cluster (see below). The clones are then sequence-verified at the 3′ end and re-transformed into a T1-phage resistant E. coli host, GeneHogs® (HS996) to eliminate identification errors and phage contamination.

The Sequence-Verified clones are cloned into a variety of vectors including the mammalian Gateway® expression vector, pCMV•SPORT6 (see page 3 for a complete list of vectors). The Gateway® Technology enables rapid transfer of genes into multiple gene expression systems (see page 3).

NCBI UniGene Cluster
UniGene is an experimental system for automatically partitioning GenBank sequences into a non-redundant set of gene-oriented clusters. Each UniGene cluster contains sequences that represent a unique gene, as well as related information such as the tissue types in which the gene has been expressed and map location.


Clone Identification
The clone identification number (ID) is a code (a 5-8 digit number) assigned by the I.M.A.G.E. Consortium.

Continued on next page
Overview, Continued

Specific Information on the Clone

Detailed information on each Sequence-Verified Clone including the clone ID, gene name, and sequence is available on CloneRanger™ from our Web site at www.invitrogen.com/clones. Clones are identified by the GenBank accession number or clone ID.

The data files for the Sequence-Verified Human and Mouse clones is available from:
ftp.resgen.com/pub/sv_libraries/, file name: RG_Hs_seq_ver_*date*.txt
ftp.resgen.com/pub/sv_libraries/, file name: RG_Mm_seq_ver_*date*.txt

These tab-delimited text files contain the following clone information:

- Vector
- Insert size
- Clone ID
- GenBank accession number
- Gene name (if known)
- Markers
- Antibiotic resistance

For more information on the clones, visit http://www.ncbi.nlm.nih.gov/dbEST/index.html
Enter an EST search code (e.g., 234589). This site includes the following information:

- Partial sequence
- Clone source
- GenBank accession number (3′ and/or 5′)
- References
- Tissue and library information

The Sequence-Verified Clones are sequenced from the 3′ end only.

The Sequence-Verified cDNA Clone Collection offered by Invitrogen was built by groups outside of Invitrogen. The quality of this collection is largely dependent on what was received from these groups. The Sequence-Verified cDNA Clones are not guaranteed to exactly match GenBank sequences. If you have determined by sequencing that the clone is incorrect, contact Technical Service (see page 7).
Overview, Continued

Vector Information
The Sequence-Verified Human cDNA Clones are cloned into the following vectors:
- pCMV•SPORT2
- pCMV•SPORT4
- pCMV•SPORT6
- Lafmid BA
- pAmp1
- pAmp10
- pBluescriptSK-
- pT7T3D-Pac
- pSPORT1

The vector pCMV•SPORT6 contains attB1 and attB2 Gateway® recombination sites (see below).

For vector maps, visit ftp://ftp.resgen.com/pub/image_vectors/
For vector sequences, visit http://image.llnl.gov/image/html/vectors.shtml

The Gateway® Technology
The Gateway® Technology is a universal cloning system that takes advantage of the site-specific recombination properties of bacteriophage lambda to provide a rapid and highly efficient way to move your gene of interest into multiple vector systems. To express your gene of interest using the Gateway® Technology, simply:

1. Recombine the Sequence-Verified cDNA Clone (in pCMV•SPORT6 vector only) containing your gene of interest with one of the pDONR™ vectors (see page vi) to generate an entry clone.
2. Generate an expression clone by performing a recombination reaction between the entry clone and a Gateway® destination vector of choice.
3. Introduce your expression clone into the appropriate host (e.g. bacterial, mammalian, yeast, insect) and express your recombinant protein.

For more information about the Gateway® Technology, refer to the Gateway® Technology manual available for downloading from our Web site at www.invitrogen.com or by contacting Technical Service (see page 7).
Using Sequence-Verified Clones

**Introduction**

General guidelines for using the Sequence-Verified cDNA Clones are described in this section.

**Preparing Glycerol Stocks**

We recommend you prepare a set of master stocks prior to using the Sequence-Verified cDNA Clones. If you have ordered the Sequence-Verified Human Library, see next page for replica plating.

To prepare 5-10 glycerol master stocks for long-term storage:

1. Streak a small portion of the glycerol stock you received on a LB plate containing 100 µg/ml ampicillin.
2. Incubate the plate at 37°C overnight.
3. Isolate a single colony and inoculate into 5-10 ml of LB containing 100 µg/ml ampicillin.
4. Grow the culture to stationary phase (OD₆₀₀ = 1-2).
5. Mix 0.8 ml of culture with 0.2 ml of sterile glycerol and transfer to a cryovial.
6. Store at -80°C. Use one master stock to create working stocks for regular use. We also recommend that you isolate and store a stock of plasmid DNA at -20°C.

**Plasmid Preparation**

To isolate plasmid DNA, you need to grow a culture of GeneHogs® *E. coli* containing your clone. Use LB medium containing 100 µg/ml ampicillin to select single colonies or to grow a culture. Use a culture volume appropriate for the amount of plasmid needed for your plasmid isolation method of choice.

We recommend isolating plasmid DNA using the S.N.A.P.™ MiniPrep Kit (10-15 µg DNA, see page vi), the S.N.A.P.™ MidiPrep Kit (10-200 µg, see page vi), or other resin-based methods.

**Note:** We recommend that you verify the clone by PCR, sequencing, or a method of choice (see next page).

*Continued on next page*
Using Sequence-Verified Clones, Continued

**Replica-Plating**
If you have ordered a Sequence-Verified Human cDNA Library, you need to produce a replica copy of the original microtiter plate. A replica copy can be generated by using replicating pins, a pin or liquid transfer robot, or a multichannel pipette.

Replica plating involves transferring a small aliquot of the clone from each well of the original microtiter plate into the corresponding well of another sterile microtiter plate containing fresh, sterile media with the appropriate antibiotic. The replica plate is incubated at an optimal temperature on an orbital shaker (to increase aeration) for at least 24 hours.


**Sequencing or PCR of Clones**
Sequence-Verified cDNA Clones are sequenced at 3’ end of the DNA only. You may verify the clone by PCR, sequencing, or a method of choice.

A primer pair, GF200.primer (see page vi) was created for amplification or sequencing of most inserts of the I.M.A.G.E Consortium/LLNL collection of cDNA clones. The primers are designed for common vector elements. The primer sequence for GF200.primer pair is:
- **Forward**: 5’-CTGCAAGGCGATTAAGTTGGGTAAC-3’
- **Reverse**: 5’-GTGAGCGGATAACAATTTCACACAGGAAACAGC-3’

Use the GF200.primer pair for sequencing or PCR with all vectors in the Sequence-Verified cDNA Clone Collection, except the vectors listed below:
- pCMV•SPORT2 (use T7 and Sp6 primers for sequencing and PCR)
- pCMV•SPORT4 (use T7 and Sp6 primers for sequencing and PCR)
- pCMV•SPORT6 (use T7 and Sp6 primers for sequencing and PCR)

*Continued on next page*
Using Sequence-Verified Clones, Continued

**Expression of Cloned cDNA**

The CMV promoter in pCMV•SPORT2, 4, and 6 vectors enable the **transient** expression of cloned cDNAs in mammalian cells.

**Note:** The pCMV•SPORT2, 4, and 6 vectors do **NOT** contain any eukaryotic origin of replication or antibiotic resistance marker for stable expression in mammalian cells. The Sequence-Verified cDNA Clones may not contain full-length sequences.

For expression of cDNA in multiple systems (prokaryotic, yeast, or insect), you need to transfer the cDNA insert to an appropriate expression vector using the Gateway® Technology (see below).

**Gateway® Cloning**

The pCMV•SPORT6 vector contains the **attB1** and **attB2** recombination sites flanking the cloning site. For expression of cDNA in multiple systems, transfer the cDNA insert from pCMV•SPORT6 vector into other Gateway®-compatible vectors, by performing a BP recombination reaction with a pDONR™ vector (see page vi).

For more details on the Gateway® cloning technology and performing the BP recombination reaction, refer to the Gateway® Technology Manual available on our Web site at www.invitrogen.com or contact Technical Service (see next page).
Technical Service

World Wide Web

Visit the Invitrogen Web Resource using your World Wide Web browser. At the site, you can:

• Get the scoop on our hot new products and special product offers
• View and download vector maps and sequences
• Download manuals in Adobe® Acrobat® (PDF) format
• Explore our catalog with full color graphics
• Obtain citations for Invitrogen products
• Request catalog and product literature

Once connected to the Internet, launch your Web browser (Internet Explorer 5.0 or newer or Netscape 4.0 or newer), then enter the following location (or URL):

http://www.invitrogen.com

...and the program will connect directly. Click on underlined text or outlined graphics to explore. Don't forget to put a bookmark at our site for easy reference!

Contact Us

For more information or technical assistance, call, write, fax, or email. Additional international offices are listed on our Web page (www.invitrogen.com).

Corporate Headquarters:
Invitrogen Corporation
1600 Faraday Avenue
Carlsbad, CA 92008 USA
Tel: 1 760 603 7200
Tel (Toll Free): 1 800 955 6288
Fax: 1 760 602 6500
E-mail: tech_service@invitrogen.com

Japanese Headquarters:
Invitrogen Japan K.K.
Nihonbashi Hama-Cho Park Bldg. 4F
2-35-4, Hama-Cho, Nihonbashi
Tel: 81 3 3663 7972
Fax: 81 3 3663 8242
E-mail: jpinfo@invitrogen.com

European Headquarters:
Invitrogen Ltd
Inchinnan Business Park
3 Fountain Drive
Paisley PA4 9RF, UK
Tel: +44 (0) 141 814 6100
Tech Fax: +44 (0) 141 814 6117
E-mail: eurotech@invitrogen.com

Continued on next page
Technical Service, Continued

MSDS Requests

Limited Warranty
Invitrogen is committed to providing our customers with high-quality goods and services. Our goal is to ensure that every customer is 100% satisfied with our products and our service. If you should have any questions or concerns about an Invitrogen product or service, please contact our Technical Service Representatives. Invitrogen warrants that all of its products will perform according to the specifications stated on the certificate of analysis. The company will replace, free of charge, any product that does not meet those specifications. This warranty limits Invitrogen Corporation’s liability only to the cost of the product. No warranty is granted for products beyond their listed expiration date. No warranty is applicable unless all product components are stored in accordance with instructions. Invitrogen reserves the right to select the method(s) used to analyze a product unless Invitrogen agrees to a specified method in writing prior to acceptance of the order. Invitrogen makes every effort to ensure the accuracy of its publications, but realizes that the occasional typographical or other error is inevitable. Therefore Invitrogen makes no warranty of any kind regarding the contents of any publications or documentation. If you discover an error in any of our publications, please report it to our Technical Service Representatives. Invitrogen assumes no responsibility or liability for any special, incidental, indirect or consequential loss or damage whatsoever. The above limited warranty is sole and exclusive. No other warranty is made, whether expressed or implied, including any warranty of merchantability or fitness for a particular purpose.
Purchaser Notification

Information for European Customers

These cells are genetically modified and contain a plasmid (see vectors listed on page 3). As a condition of sale, this product must be in accordance with all applicable local legislation and guidelines including EC Directive 90/219/EEC on the contained use of genetically modified organisms.

Limited Use Label

License No. 19: Gateway® Cloning Products

The Gateway® Cloning Technology products and their use are the subject of one or more of U.S. Patent Nos. 5,888,732, 6,143,557, 6,171,861, 6,270,969, and 6,277,608 and/or other pending U.S. and foreign patent applications owned by Invitrogen Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). No license is conveyed under the foregoing patents to use this product with any recombination sites other than those purchased from Invitrogen Corporation or its authorized distributor. The buyer cannot modify the recombination sequence(s) contained in this product for any purpose. The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Invitrogen Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Continued on next page
Limited Use Label
License No. 28:
CMV Promoter

The use of the CMV promoter is covered under U.S. Patent Nos. 5,168,062 and 5,385,839 owned and licensed by the University of Iowa Research Foundation and is sold for research use only. Commercial users must obtain a license to these patents directly from the University of Iowa Research Foundation (UIRF), 214 Technology Innovation Center, Iowa City, Iowa 52242. For further information, please contact the Associate Director of UIRF, at 319-335-4546.

©2002-2003 Invitrogen Corporation. All rights reserved.

For research use only. Not intended for any animal or human therapeutic or diagnostic use.